Teva Pharmaceuticals Australia Pty Ltd

Teva Pharmaceuticals Ausralia Pty Ltd

Stephen Tran

Anthony Gerard Doyle

Adam Clarke

Matthew Pollard

Sarah Lee Pogue

Glen Eugene Mikesell

Wouter Korver

David S Wilson, Jr

Tetsuya Taura

Jack Tzu Chiao Lin

David S Wilson

Jack Tzu-Chiao Lin

Jr David S Wilson

Antony G Doyle

The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.

Fusions of antibodies to CD38 and attenuated interferon alpha

The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.

Anti-IL-23 heterodimer specific antibodies

Growing community of inventors

Strathfield South, Australia

Stephen Tran